Abbott (ABT) is a publicly traded Neuromodulation & Stimulation company based in Chicago, United States.
No dated funding rounds on file. This company is privately held and may be raising or operating on undisclosed capital.
Abbott is one of the three incumbents that own clinical neuromodulation, defended by FDA-approved SCS and DBS platforms, proprietary BurstDR waveforms, and the switching cost of an implant a physician has already programmed. Pricing power is real but capped: device reimbursement is negotiated against CMS and payer schedules rather than set freely, so the moat shows up in volume and retention, not price increases. The diversified parent's balance sheet easily funds the multi-year trial and R&D cycles the category demands. The live risk is that closed-loop sensing and next-generation BCIs eventually reach the same indications, though displacing an installed implant base is a decade-scale threat, not a near one.
No articles ingested yet for Abbott. Once the hourly news pipeline is live, every article the classifier tags as mentioning this company appears here with its one-line AI summary and sentiment.
FDA-approved recharge-free spinal cord stimulation (SCS) system delivering Abbott's proprietary BurstDR stimulation waveform for chronic neuropathic pain and painful diabetic peripheral neuropathy. Battery life up to 10 years at low-dose settings without charging. Integrates with the NeuroSphere Virtual Clinic app, allowing remote physician programming and treatment adjustments, reducing clinic visits for patients with implanted devices.
Rechargeable spinal cord stimulator featuring Abbott's Xtend energy technology, reducing charging to as few as five times per year — the lowest recharge burden on the market. FDA-cleared for chronic pain management. Designed to deliver BurstDR stimulation across a wide range of pain indications, with programmable sub-perception and paresthesia-based modes.
Rechargeable deep brain stimulation (DBS) implant for Parkinson's disease and essential tremor, featuring the longest-lasting battery charge and smallest IPG profile in Abbott's DBS portfolio. Offers first-of-its-kind remote programming capability, allowing neurologists to adjust stimulation parameters outside the clinic via the NeuroSphere Virtual Clinic digital health platform.
305 patents on file, but none with both an extractable figure and an abstract on Google Patents yet.